http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
배지철,Lauren A. Beste,Kristina M. Utzschneider 대한내분비학회 2022 Endocrinology and metabolism Vol.37 No.3
Background: We aimed to investigate the association of hepatic steatosis with liver fibrosis and to assess the interactive effects ofhepatic steatosis and insulin resistance on liver fibrosis in a nationally representative sample of United States adults. Methods: We conducted a cross-sectional analysis using data from National Health and Nutrition Examination Survey 2017 to2018, which for the first time included transient elastography to assess liver stiffness and hepatic steatosis. We evaluated the association between hepatic steatosis (using controlled attenuation parameter [CAP]) and clinically significant liver fibrosis (defined as liverstiffness ≥7.5 kPa) using logistic regression with an interaction term for hepatic steatosis and insulin resistance (defined as homeostatic model assessment of insulin resistance ≥3.0). Results: Among adults undergoing transient elastography (n=2,023), 45.9% had moderate or greater hepatic steatosis and 11.3%had clinically significant liver fibrosis. After adjustment for demographic and metabolic factors, the odds of significant liver fibrosisincreased as CAP score rose (odds ratio, 1.35 per standard deviation increment; 95% confidence interval, 1.11 to 1.64). We detecteda significant interaction effect between CAP score and insulin resistance on the probability of significant liver fibrosis (P=0.016 forinteraction). The probability of significant liver fibrosis increased in the presence of insulin resistance with increasing CAP score,while those without insulin resistance had low probability of significant liver fibrosis, even with high CAP scores. Conclusion: Individuals with hepatic steatosis had higher odds of fibrosis when insulin resistance was present. Our findings emphasize the importance of the metabolic aspects of the disease on fibrosis risk and suggest a need to better identify patients with metabolic associated fatty liver disease.